Todd Levin, MD
Allergy & Immunology · Chattanooga, TNNPI 1487623989
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $51,120 of the $64,285 with a category attached, or 79.5%. GSK accounts for 62.4% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2021 at $17,972 and has fallen 72.5% since, to $4,939 in 2025.
Across 744 payments — averaging $86.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$40K
- Pfizer$7K
- Teva Pharmaceuticals USA, Inc.$5K
- AstraZeneca$4K
- Regeneron Healthcare Solutions, Inc.$1K
- CSL Behring$918
- plus $7K from 34 others
What the payments were for
- Speaking & faculty fees$51,12080%
- Food & beverage$13,02120%
- Education$1440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$20,800
- AREXVY$12,791
- EUCRISA$5,430
- ProAir Digihaler$5,040
- AirDuo RespiClick$5,040
- ArmonAir Digihaler$5,040
- TEZSPIRE$2,466
- FASENRA$366
- AIRSUPRA$366
- CUTAQUIG$144
How this compares
$64,285 in reported general payments places this provider in the 85th percentile of 79 allergy & immunology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 109 | $475,710 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 389 | $323,979 |
| TezspireTezepelumab-Ekko | 70 | $286,079 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 138 | $99,267 |
| FasenraBenralizumab | 16 | $94,800 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 25 | $90,058 |
| Dupixent SyringeDupilumab | 16 | $83,505 |
| Dupixent PenDupilumab | 20 | $75,418 |
| NucalaMepolizumab | 20 | $75,245 |
| XembifyImmune Globulin,gamma(Igg)klhw | 13 | $72,822 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 18 | $57,692 |
| Breo ElliptaFluticasone/Vilanterol | 76 | $51,162 |
| Spiriva RespimatTiotropium Bromide | 53 | $43,510 |
| SymbicortBudesonide/Formoterol Fumarate | 116 | $32,949 |
| Epinephrine | 125 | $26,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Fasenra, Symbicort | $3,700 | $513,095340 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $40,084 | $469,973551 claims |
| CSL BehringHizentra | $918 | $90,05825 claims |
| Grifols USA, LLCXembify | $594 | $72,82213 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $896 | $57,69218 claims |
| Boehringer IngelheimSpiriva Respimat | $99 | $43,51053 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $5,148 | $12,40031 claims |
| MerckDulera | $22 | $8,18619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 79 allergy & immunology providers in Tennessee.
Other allergy & immunology in Chattanooga
- Marc CromieChattanooga$106K
- Susan RaschalChattanooga$40K
- Jennifer PatelChattanooga$12K
- Lee PerryChattanooga$10K
- Joseph WisniewskiChattanooga$6K
- David ChaffinChattanooga$5K
- Jessica van MasonChattanooga$5K
- Taylor AtchleyChattanooga$4K
- Michael HollieChattanooga$3K
- Paul CarterChattanooga$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.